Skip to main content

Table 3 SETBP1 mutations in atypical CML and unclassifiable MDS/MPN

From: SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome

 

Reference

Number of Patients

Mutation Prevalence

Impact on Survival

Atypical CML

[34]

70

17 (24.3%)

Yes (p-0.01)

[32]

60

19 (32.1%)

No (p-0.191)

Unclassifiable MDS/MPN

[34]

30

3 (10%)

NR

[32]

240

20 (9.3%)

NR

  1. NR Not reported